Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinobioway Enters $50 Million Deal for Five BioAtla CAB Candidates

publication date: May 16, 2017
Beijing Sinobioway added five new Conditionally Active Biologic antibody targets to its collaboration with BioAtla, a San Diego-Beijing biotech. Sinobioway will pay $50 million to BioAtla for China rights to the new targets, consisting of $30 million in cash and $20 million in manufacturing and development costs (at a discounted rate). In 2015, Sinobioway in-licensed greater China rights to four CAB candidates from BioAtla. The two companies have also signed a new services agreement that calls for Sinobioway to provide BioAtla with development and manufacturing services. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital